

<b>Patient data (n=41)</b>	
Age (years), median (IQR)	62 (50–69)
Sex ratio (Male/Female)	2.4
BMI (kg/m <sup>2</sup> ), median (IQR)	23.7 (20.8–26.5)
<b>Medical history</b>	
Hypertension, n (%)	21 (51.2%)
Chronic obstructive pulmonary disease, n (%)	5 (12.2%)
Chronic kidney disease, n (%)	9 (22.0%)
Cancer, n (%)	5 (12.2%)
Diabetes mellitus, n (%)	12 (29.3%)
Cirrhosis, n (%)	1 (2.4%)
Immunosuppression, n (%)	6 (14.6%)
SAPS II, mean ± SD	46 ± 20
<b>Clinical status data at complete echocardiographic examination (n=50)</b>	
<b>Macrohaemodynamic parameters</b>	
Mean arterial pressure (mmHg), mean ± SD	87 ± 17
Pulse pressure (mmHg), mean ± SD	53 ± 20
Heart rate (bpm), median (IQR)	89 (76–108)
<b>Acute circulatory failure, n %</b>	
Septic, n %	11 (50.0%)
Cardiogenic, n %	5 (22.7%)
Vasoplegic, n %	4 (18.2%)
Obstructive, n %	0 (0.0%)
Mixed, n %	2 (9.1%)
<b>Vasopressor/inotropic support, n %</b>	
Norepinephrine, n %	20 (90.9%)
Median dose (µg/kg/min) (IQR)	0.32 (0.15–0.74)
Arginine vasopressin, n %	6 (27.3%)
Median dose (µg/kg/min) (IQR)	0.03 (0.03–0.03)
Dobutamine, n %	7 (31.8%)
Median dose (µg/kg/min) (IQR)	5.0 (2.5–5)
Atrial fibrillation, n %	6 (12.0%)
<b>Ventilatory/oxygen support</b>	
Invasive mechanical ventilation, n %	25 (64.1%)
High-flow nasal oxygen, n %	8 (20.5%)
NIV, n %	0 (0.0%)
Conventional oxygen therapy, n %	6 (15.4%)
ARDS, n %	11 (26.8%)
PEEP if intubated or NIV (cmH <sub>2</sub> O), median (IQR)	7 (5–8)
Sedation, n %	17 (41.5%)
Continuous renal replacement therapy, n %	5 (12.2%)